LT3793995T - Matrikso metaloproteinazės (mmp) inhibitoriai ir jų naudojimo būdai - Google Patents

Matrikso metaloproteinazės (mmp) inhibitoriai ir jų naudojimo būdai

Info

Publication number
LT3793995T
LT3793995T LTEPPCT/US2019/032131T LTUS2019032131T LT3793995T LT 3793995 T LT3793995 T LT 3793995T LT US2019032131 T LTUS2019032131 T LT US2019032131T LT 3793995 T LT3793995 T LT 3793995T
Authority
LT
Lithuania
Prior art keywords
mmp
inhibitors
methods
matrix metalloproteinase
metalloproteinase
Prior art date
Application number
LTEPPCT/US2019/032131T
Other languages
English (en)
Lithuanian (lt)
Inventor
Wenjin Yang
Kai-Wei Chang
Suying Liu
Cheng-Han Tsai
Original Assignee
Foresee Pharmaceuticals Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foresee Pharmaceuticals Usa, Inc. filed Critical Foresee Pharmaceuticals Usa, Inc.
Publication of LT3793995T publication Critical patent/LT3793995T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/US2019/032131T 2018-05-15 2019-05-14 Matrikso metaloproteinazės (mmp) inhibitoriai ir jų naudojimo būdai LT3793995T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671753P 2018-05-15 2018-05-15
PCT/US2019/032131 WO2019222157A1 (en) 2018-05-15 2019-05-14 Matrix metalloproteinase (mmp) inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
LT3793995T true LT3793995T (lt) 2024-04-25

Family

ID=66690981

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2019/032131T LT3793995T (lt) 2018-05-15 2019-05-14 Matrikso metaloproteinazės (mmp) inhibitoriai ir jų naudojimo būdai

Country Status (20)

Country Link
US (6) US11739080B2 (cg-RX-API-DMAC7.html)
EP (4) EP3793992B1 (cg-RX-API-DMAC7.html)
JP (4) JP7343571B2 (cg-RX-API-DMAC7.html)
KR (3) KR102861502B1 (cg-RX-API-DMAC7.html)
CN (3) CN119462623A (cg-RX-API-DMAC7.html)
AU (3) AU2019270975B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020023269A2 (cg-RX-API-DMAC7.html)
CA (2) CA3100319A1 (cg-RX-API-DMAC7.html)
DK (2) DK3793995T3 (cg-RX-API-DMAC7.html)
ES (2) ES2984594T3 (cg-RX-API-DMAC7.html)
FI (2) FI3793992T3 (cg-RX-API-DMAC7.html)
HU (2) HUE066627T2 (cg-RX-API-DMAC7.html)
LT (1) LT3793995T (cg-RX-API-DMAC7.html)
MY (1) MY199200A (cg-RX-API-DMAC7.html)
PL (1) PL3793995T3 (cg-RX-API-DMAC7.html)
PT (2) PT3793995T (cg-RX-API-DMAC7.html)
SG (2) SG11202011318QA (cg-RX-API-DMAC7.html)
SI (1) SI3793995T1 (cg-RX-API-DMAC7.html)
TW (3) TWI827601B (cg-RX-API-DMAC7.html)
WO (2) WO2019222154A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532102B2 (en) * 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
SG11202011318QA (en) * 2018-05-15 2020-12-30 Foresee Pharmaceuticals Usa Inc Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
DK4058437T3 (da) 2019-11-14 2025-01-20 Foresee Pharmaceuticals Usa Inc Matrix-metalloproteinase-(MMP)-inhibitorer og fremgangsmåder til anvendelse heraf
JP2024520818A (ja) * 2021-06-08 2024-05-24 フォアシー ファーマシューティカルズ カンパニー リミテッド 急性呼吸促迫症候群を処置するためのmmp阻害薬の使用
KR20240019265A (ko) * 2021-06-08 2024-02-14 포시 파마슈티컬스 컴퍼니 리미티드 Mmp-12 억제제의 안전한 투여
EP4198033A1 (en) 2021-12-14 2023-06-21 Basf Se Heterocyclic compounds for the control of invertebrate pests
WO2023110473A1 (en) 2021-12-14 2023-06-22 Basf Se Heterocyclic compounds for the control of invertebrate pests

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2482618A1 (fr) 1980-05-16 1981-11-20 Inst Corps Gras Iterg Procede de conjugaison catalytique de corps gras polyinsatures, produits obtenus et application
AU1817700A (en) 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6352976B1 (en) 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
AU4882101A (en) 2000-04-28 2001-11-12 Shionogi & Co., Ltd. Mmp-12 inhibitors
SE0100903D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
MXPA03008180A (es) * 2001-03-15 2003-12-12 Astrazeneca Ab Inhibidores de metaloproteinasa.
ATE445400T1 (de) 2001-05-25 2009-10-15 Bristol Myers Squibb Co Hydantion-derivate als hemmer von matrix- metalloproteinasen
EP1394159A1 (fr) 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
WO2004033632A2 (en) * 2002-10-04 2004-04-22 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
US7132432B2 (en) * 2003-06-05 2006-11-07 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
ES2364068T3 (es) * 2004-08-19 2011-08-24 Quest Pharmaceutical Services 5-[3-(4-benciloxifeniltio)-fur-2-il]-imidazolin-2,4-diona y sus análogos como inhibidores de macrófago elastasa.
JP5357365B1 (ja) 2011-12-21 2013-12-04 パナソニック株式会社 データ処理装置、データ送信装置、データ処理システム、データ処理方法、及び、データ送信方法
SG11202011318QA (en) * 2018-05-15 2020-12-30 Foresee Pharmaceuticals Usa Inc Matrix metalloproteinase (mmp) inhibitors and methods of use thereof

Also Published As

Publication number Publication date
EP3793995B1 (en) 2024-01-10
US20250115590A1 (en) 2025-04-10
DK3793995T3 (da) 2024-04-08
PT3793992T (pt) 2024-05-13
HUE066627T2 (hu) 2024-08-28
US10851089B2 (en) 2020-12-01
EP4349332A3 (en) 2024-05-15
DK3793992T3 (da) 2024-04-08
EP3793992B1 (en) 2024-01-10
CN112424192B (zh) 2024-11-26
TW202400584A (zh) 2024-01-01
AU2019270975B2 (en) 2023-12-14
TW202003493A (zh) 2020-01-16
US20210214340A1 (en) 2021-07-15
CN119462623A (zh) 2025-02-18
FI3793995T3 (fi) 2024-04-17
TW202002975A (zh) 2020-01-16
KR20250021604A (ko) 2025-02-13
US12258335B1 (en) 2025-03-25
FI3793992T3 (fi) 2024-04-17
US20190352288A1 (en) 2019-11-21
EP3793992A1 (en) 2021-03-24
ES2978192T3 (es) 2024-09-06
JP2021523240A (ja) 2021-09-02
AU2024200323A1 (en) 2024-02-01
KR20210020897A (ko) 2021-02-24
MY199200A (en) 2023-10-19
AU2019269409B2 (en) 2023-11-23
JP7343571B2 (ja) 2023-09-12
KR20210020011A (ko) 2021-02-23
US11739080B2 (en) 2023-08-29
EP4335499A3 (en) 2024-05-15
CN112424186A (zh) 2021-02-26
US20240018131A1 (en) 2024-01-18
SG11202011318QA (en) 2020-12-30
TWI798435B (zh) 2023-04-11
PT3793995T (pt) 2024-05-02
SI3793995T1 (sl) 2024-05-31
JP7656669B2 (ja) 2025-04-03
US20190352287A1 (en) 2019-11-21
TWI895726B (zh) 2025-09-01
US12215096B2 (en) 2025-02-04
CA3100320A1 (en) 2019-11-21
WO2019222157A1 (en) 2019-11-21
JP7344959B2 (ja) 2023-09-14
KR102861502B1 (ko) 2025-09-18
PL3793995T3 (pl) 2024-05-06
AU2019269409A1 (en) 2021-01-07
KR102761591B1 (ko) 2025-01-31
ES2984594T3 (es) 2024-10-30
EP4349332A2 (en) 2024-04-10
TWI827601B (zh) 2024-01-01
HUE066619T2 (hu) 2024-08-28
CA3100319A1 (en) 2019-11-21
CN112424192A (zh) 2021-02-26
WO2019222154A1 (en) 2019-11-21
EP4335499A2 (en) 2024-03-13
AU2024200323B2 (en) 2025-06-05
JP2023164905A (ja) 2023-11-14
JP2023164924A (ja) 2023-11-14
EP3793995A1 (en) 2021-03-24
BR112020023269A2 (pt) 2021-02-23
SG11202011316RA (en) 2020-12-30
EP4349332B1 (en) 2026-07-15
AU2019270975A1 (en) 2021-01-07
JP2021523241A (ja) 2021-09-02

Similar Documents

Publication Publication Date Title
IL287940A (en) Fgfr inhibitors and methods of use thereof
IL283592A (en) Inhibitors of apol1 and methods of using same
IL282487A (en) Tyk2 inhibitors and uses thereof
IL287751A (en) Kcnt1 inhibitors and methods of use
IL287768A (en) Kcnt1 inhibitors and methods of use
IL284640A (en) Pcsk9 inhibitors and methods of use thereof
IL284661A (en) Pcsk9 inhibitors and methods of use thereof
DK3966207T3 (da) Phenylaminopyrimidinamid-autophagi-hæmmere og fremgangsmåder til anvendelse deraf
DK3966206T3 (da) Heteroarylaminopyrimidinamid-autophagihæmmere og fremgangsmåder til anvendelse deraf
IL283106A (en) Erk inhibitors and uses thereof
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
IL282090A (en) Tyk2 inhibitors and uses thereof
DK3761980T3 (da) Aminosyreforbindelser og fremgangsmåder til anvendelse
DK3793992T3 (da) Matrix metalloproteinase (MMP)-inhibitorer og fremgangsmåder til anvendelse deraf
DK3710430T3 (da) Acss2-inhibitorer og fremgangsmåder til anvendelse deraf
EP3801500A4 (en) Inhibitors of sarm1
IL283782A (en) Anellosomes and methods of use
IL280761A (en) Devices and systems for body cavities and methods of use
HRP20251592T1 (hr) Inhibitori arginaze i metode njihove primjene
IL291217A (en) Usp30 inhibitors and uses thereof
DK3543240T3 (da) URAT1-inhibitor og anvendelse deraf
LT3840837T (lt) Arginazės inhibitoriai ir jų panaudojimo būdai
IL286485A (en) Pi4-kinase inhibitors and methods of using the same
IL263506A (en) Topical formulations of pde-4 inhibitors and their methods of use
EP4017857A4 (en) METTL 16 INHIBITORS AND THEIR USES